Fig. 9.

Loss of HSPG2 in the stroma improves the efficacy of gemcitabine/Abraxane in vivo. a Schematic representation of subcutaneous injection and treatment timeline, b quantification of tumor volume and c. time to experimental endpoint for mice subcutaneously injected with mt-CCs + mt-e-CAFs WT and treated with saline (n = 7) or with gemcitabine/Abraxane (n = 6) or with mt-CCs + mt-e-CAFs KO HSPG2 and treated with saline (n = 7) or with gemcitabine/Abraxane (n = 6). d Schematic representation of orthotopic (in pancreas) injection and treatment timeline, and e survival for mice orthotopically injected with mt-COs + mt-e-CAFs WT and treated with saline (n = 5) or with gemcitabine/Abraxane (n = 10) or with mt-CCs + mt-e-CAFs KO HSPG2 and treated with saline (n = 7) or with gemcitabine/Abraxane (n = 5). f Schematic summary of main findings. *p < 0.05, **p < 0.01, ***p < 0.001